Computer-Automated Dementia Screening Using a Touch-Tone Telephone

Mundt, James C.; Ferber, Kae L.; Rizzo, Matthew; Greist, John H.

doi:10.1001/archinte.161.20.2481

Cited by 41 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternative communication modes such as videoconferencing and computer-automated or computer-assisted telephone screening, while at an early stage of development, show promise for the future [68][69][70]. Although it might be possible to adapt the MATS to one of these formats, it remains to be seen whether these technologies become widely available, cost-effective, and readily embraced by older adults.…”

Section: Discussionmentioning

confidence: 99%

The Memory and Aging Telephone Screen: Development and preliminary validation

Rabin

Saykin

Wishart

et al. 2007

Alzheimer's & Dementia

View full text Add to dashboard Cite

Background-Telephone interviews are widely used in geriatric settings to identify eligible research participants and to perform brief follow-up assessments of cognition. This article reports on the development and validation of the Memory and Aging Telephone Screen (MATS), a structured interview for older adults with mild cognitive impairment and/or significant memory complaints. We also developed three alternate forms of the MATS objective memory test to reduce practice effects engendered by multiple administrations.Methods-Participants were enrolled in a longitudinal study that included 120 older adults with amnestic mild cognitive impairment (MCI), subjective cognitive complaints (CC) but without deficit on neuropsychological tests, and demographically-matched healthy controls (HC). An additional 15 patients with mild probable Alzheimer's disease (AD) completed the alternative forms study. All participants received the original MATS version, and a subset (n = 90) later received two of three alternate forms.Results-The MATS was sensitive to group differences and the alternate forms were equivalent. MATS objective memory test scores showed adequate stability over one year and were moderately correlated with scores on a widely used list-learning test (CVLT-II).Conclusions-The MATS, a repeatable telephone screen that includes objective and subjective memory assessments, is useful for detecting individuals in the preclinical and early stages of dementia. Results encourage use of the MATS as a reliable and valid cognitive screening tool in research and clinical settings. Longitudinal assessments are being performed to investigate the predictive validity of the MATS for cognitive progression in MCI.

show abstract

Section: Discussionmentioning

confidence: 99%

The Memory and Aging Telephone Screen: Development and preliminary validation

Rabin

Saykin

Wishart

et al. 2007

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…Five studies reported results for more than two groups of participants: three included healthy controls, MCI and early dementia, 71,76,86 and two included healthy controls, early dementia and early dementia/MCI combined. 70,74 In total, 10 studies 68,69,71,72,75,76,78,79,85,86 evaluated the use of automated computerised tests to detect MCI alone, seven studies 70,71,74,76,80,81,86 reported results for early dementia, three studies 70,74,77 reported results for combined MCI/early dementia and one study 83 reported results for human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND).…”

Section: Included Studiesmentioning

confidence: 99%

“…[68][69][70][77][78][79][80]85 The studies were judged to be at high risk for this criterion because a case-control study design was used. Regarding the index test criteria for risk of bias, seven studies 70,71,74,76,78,83,85 were judged to be at unclear risk.…”

Section: Study Quality Assessmentmentioning

confidence: 99%

“…The reference standard domain for the risk of bias was unclear in eight studies, 68,69,72,75,[79][80][81]86 as it was not possible to ascertain whether or not reference standard results were interpreted without knowledge of the results of the index tests. However, the reference standard used in each of the studies was likely to correctly classify the target condition.…”

Section: Study Quality Assessmentmentioning

confidence: 99%

“…Even though all of the tests were self-administered, a practice session was offered to participants in five studies [69][70][71]79,86 to make sure that patients were familiar with the software and platform for the index test. Nine studies 68,69,71,72,75,[77][78][79][80] reported that support staff were present in the room to address any questions from participants about the software or platform. …”

Section: Index Test Detailsmentioning

confidence: 99%

See 2 more Smart Citations

Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review

Aslam

Bates

Dündar

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

BackgroundCognitive impairment is a growing public health concern, and is one of the most distinctive characteristics of all dementias. The timely recognition of dementia syndromes can be beneficial, as some causes of dementia are treatable and are fully or partially reversible. Several automated cognitive assessment tools for assessing mild cognitive impairment (MCI) and early dementia are now available. Proponents of these tests cite as benefits the tests’ repeatability and robustness and the saving of clinicians’ time. However, the use of these tools to diagnose and/or monitor progressive cognitive impairment or response to treatment has not yet been evaluated.ObjectivesThe aim of this review was to determine whether or not automated computerised tests could accurately identify patients with progressive cognitive impairment in MCI and dementia and, if so, to investigate their role in monitoring disease progression and/or response to treatment.Data sourcesFive electronic databases (MEDLINE, EMBASE, The Cochrane Library, ISI Web of Science and PsycINFO), plus ProQuest, were searched from 2005 to August 2015. The bibliographies of retrieved citations were also examined. Trial and research registers were searched for ongoing studies and reviews. A second search was run to identify individual test costs and acquisition costs for the various tools identified in the review.Review methodsTwo reviewers independently screened all titles and abstracts to identify potentially relevant studies for inclusion in the review. Full-text copies were assessed independently by two reviewers. Data were extracted and assessed for risk of bias by one reviewer and independently checked for accuracy by a second. The results of the data extraction and quality assessment for each study are presented in structured tables and as a narrative summary.ResultsThe electronic searching of databases, including ProQuest, resulted in 13,542 unique citations. The titles and abstracts of these were screened and 399 articles were shortlisted for full-text assessment. Sixteen studies were included in the diagnostic accuracy review. No studies were eligible for inclusion in the review of tools for monitoring progressive disease. Eleven automated computerised tests were assessed in the 16 included studies. The overall quality of the studies was good; however, the wide range of tests assessed and the non-standardised reporting of diagnostic accuracy outcomes meant that meaningful synthesis or statistical analysis was not possible.LimitationsThe main limitation of this review is the substantial heterogeneity of the tests assessed in the included studies. As a result, no meta-analyses could be undertaken.ConclusionThe quantity of information available is insufficient to be able to make recommendations on the clinical use of the computerised tests for diagnosing and monitoring MCI and early dementia progression. The value of these tests also depends on the costs of acquisition, training, administration and scoring.Future workResearch is required to establish stable cut-off points for automated computerised tests that are used to diagnose patients with MCI or early dementia. Additionally, the costs associated with acquiring and using these tests in clinical practice should be estimated.Study registrationThe study is registered as PROSPERO CRD42015025410.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract